Rodolfo Soria-Castro

Rodolfo Soria-Castro

Auto-generated profile, based on publicly available information

Rodolfo Soria-Castro

Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional (ENCB-IPN), Mexico City, Mexico

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2019 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
RSRodolfo Soria-Castro
Rodolfo Soria-Castro
ASAlejandro Schcolnik-Cabrera
Alejandro Schcolnik-Cabrera
GRGloria Rodríguez-López
Gloria Rodríguez-López
MCMarcia Campillo-Navarro
Marcia Campillo-Navarro
NPNahum Puebla-Osorio
Nahum Puebla-Osorio
ABALMA DELIA CHAVEZ BLANCO
ALMA DELIA CHAVEZ BLANCO
Valproic acid (VPA) is widely recognized for its use in the control of epilepsy and other neurological disorders in the past 50 years. Recent evidence has shown the potential of VPA in the control of certain cancers, owed in part to its role in modulating epigenetic changes through the inhibition of histone deacetylases, affecting the expression of genes involved in the cell cycle, differentiation, and apoptosis. The direct impact of VPA in cells of the immune system has only been explored recently. In this review, we discuss the effects of VPA in the suppression of some activation mechanisms in several immune cells that lead to an anti-inflammatory response. As expected, immune cells are not exempt from the effect of VPA, as it also affects the expression of genes of the cell cycle and apoptosis through epigenetic modifications. In addition to inhibiting histone deacetylases, VPA promotes RNA interference, activates histone methyltransferases, or represses the activation of transcription factors. However, during the infectious process, the effectiveness of VPA is subject to the biological nature of the pathogen and the associated immune response; this is because VPA can promote the control or the progression of the infection. Due to its various effects, VPA is a promising alternative for the control of autoimmune diseases and hypersensitivity and needs to be further explored.

28 May 2018 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
MCMarcia Campillo-Navarro
Marcia Campillo-Navarro
KLKahiry Leyva-Paredes
Kahiry Leyva-Paredes
LDLuis Donis-Maturano
Luis Donis-Maturano
GRGloria M. Rodríguez-López
Gloria M. Rodríguez-López
RSRodolfo Soria-Castro
Rodolfo Soria-Castro
RCRommel Chacon-Salinas
Rommel Chacon-Salinas
Tuberculosis is one of the leading causes of human morbidity and mortality. Mycobacterium tuberculosis (Mtb) employs different strategies to evade and counterattack immune responses persisting for years. Mast cells are crucial during innate immune responses and help clear infections via inflammation or by direct antibacterial activity through extracellular traps (MCETs). Whether Mtb induce MCETs production is unknown. In this study, we report that viable Mtb did not induce DNA release by mast cells, but heat-killed Mtb (HK-Mtb) did. DNA released by mast cells after stimulation with HK-Mtb was complexed with histone and tryptase. MCETs induced with PMA and HK-Mtb were unable to kill live Mtb bacilli. Mast cells stimulated with HK-Mtb induced hydrogen peroxide production, whereas cells stimulated with viable Mtb did not. Moreover, MCETs induction by HK-Mtb was dependent of NADPH oxidase activity, because its blockade resulted in a diminished DNA release by mast cells. Interestingly, catalase-deficient Mtb induced a significant production of hydrogen peroxide and DNA release by mast cells, indicating that catalase produced by Mtb prevents MCETs release by degrading hydrogen peroxide. Our findings show a new strategy employed by Mtb to overcome the immune response through inhibiting MCETs formation, which could be relevant during early stages of infection.

6 October 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
AMAdriana I. Muñoz
Adriana I. Muñoz
Luis Vallejo-CastilloLuis Vallejo-Castillo
Luis Vallejo-Castillo
AFAna Fragozo
Ana Fragozo
SVSaid Vázquez-Leyva
Said Vázquez-Leyva
Lenin PavónLenin Pavón
Lenin Pavón
SPSonia Mayra Pérez-Tapia
Sonia Mayra Pérez-Tapia
Canine parvovirus type II (CPV-2) infection induces canine parvoviral enteritis (CPE), which in turn promotes sepsis and systemic inflammatory response syndrome (SIRS). Mortality in this disease is usually registered within 48–72 h post-hospitalization, the critical period of the illness. It has been recently described that the use of an immunomodulator, whose major component is monomeric ubiquitin (mUb) without the last two glycine residues (Ub∆GG), in pediatric human patients with sepsis augments survival. It is known that CXCR4 is the cell receptor of extracellular ubiquitin in humans. This work aimed to explore the effect of one immunomodulator (human Dialyzable Leukocyte Extract-hDLE) as a therapeutic auxiliary in puppies with sepsis and SIRS induced by CPE. We studied two groups of puppies with CPV-2 infection confirmed by polymerase chain reaction. The first group received conventional treatment (CT) and vehicle (V), while the second group received CT plus the immunomodulator (I). We assessed both groups' survival, clinical condition, number of erythrocytes, neutrophils, and lymphocytes during the hospitalization period. In addition, hematocrit, hemoglobin, plasma proteins and cortisol values, as well as norepinephrine/epinephrine and serotonin concentration were determined. Puppies treated with CT + I showed 81% survival, mild clinical signs, and a significant decrease in circulating neutrophils and lymphocytes in the critical period of the treatment. In contrast, the CT + V group presented a survival of 42%, severe clinical status, and no improvement of the parameters evaluated in the critical period of the disease. We determined in silico that human Ub∆GG can bind to dog CXCR4. In conclusion, the administration of a human immunomodulator (0.5 mg/day × 5 days) to puppies with CPE under six months of age reduces the severity of clinical signs, increases survival, and modulates inflammatory cell parameters. Further studies are necessary to take full advantage of these clinical findings, which might be mediated by the human Ub∆GG to canine CXCR4 interaction.

24 July 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
ASAlejandro Schcolnik-Cabrera
Alejandro Schcolnik-Cabrera
MRMarisol Ramírez-Yautentzi
Marisol Ramírez-Yautentzi
RSRodolfo Soria-Castro
Rodolfo Soria-Castro
RCRommel Chacón-Salinas
Rommel Chacón-Salinas
RMRocio Rocio Morales
Rocio Rocio Morales
ABALMA DELIA CHAVEZ BLANCO
ALMA DELIA CHAVEZ BLANCO